95

Interventional Oncology Market

Interventional Oncology Market to Reach USD 4.4 Billion by 2031, driven by the growth in investment in healthcare infrastructure across the globe: Global Insight Services

New York, August 2022: According to a new research study by Global Insight Services (GIS), the global interventional oncology market is expected to grow rapidly over the next 10 years to reach a value of more than USD 4.4 billion by 2031.

Interventional oncology procedures include cancer detection and therapy using minimally invasive techniques carried out with the use of images. For guidance, the procedure makes use of tools like x-ray, ultrasound, computed tomography, or magnetic resonance imaging. With the aid of image guidance during interventional oncology operations, cancer is targeted and eliminated. Such procedures are performed either under CT/USG guidance or in a state-of-the-art oncology Cath Lab. Ablation electrode, guidewires, biopsy needles, and intravascular catheters are used during the operations in order to treat tumors that are located in difficult-to-reach areas of the body.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10310/

Interventional Oncology Market: Key Trends and Drivers

Due to the benefits these procedures offer over conventional treatment methods, the demand for minimally invasive procedures has significantly increased in recent years. Fewer postoperative complications, a shorter hospital stay, less pain, smaller and more cosmetic incisions, a lower risk of infection, less post-operative care, and a speedier recovery time are the main benefits of minimally invasive procedures. Modern technology is used in minimally invasive procedures to identify and treat diseases like cancer. These techniques are utilized as an efficient way to remove cancerous lymph nodes and tumors without leaving scars. The collection of tissues for biopsies and precise staging tests are both made possible by minimally invasive surgical methods. In turn, this aids surgeons in developing a precise and appropriate cancer treatment strategy. Significant cost savings are also achieved through the use of minimally invasive procedures. The major competitors in the interventional oncology market are concentrating more and more on introducing cutting-edge products. The development of affordable, cutting-edge technology, and user-friendly interventional oncology systems is the main focus of innovation in this market. Such developments concentrate on enhancing the capability of interventional oncology systems and broadening their application domains, which raises end customers’ demand for these systems.

Interventional Oncology Market: Restraints and Challenges

The interventional oncology industry is always experiencing technical developments and advancements that improve the precision and specificity of the equipment and treatments. However, full-time professionals are required to establish and maintain excellent standards in interventional oncology. The lack of qualified radiologists and oncologists is therefore anticipated to have an impact on the expansion of the interventional oncology industry. For instance, the US is predicted to experience a shortage of more than 2,300 medical oncologists by 2025. (Source: Journal of Global Oncology). This aspect will have a greater impact in developing and impoverished areas. The lack of medical oncologists, radiation oncologists, and other healthcare professionals needed for cancer care in the sub-Saharan African region is one of the main challenges to providing treatment for people with treatable tumors. Similar to this, there is a severe lack of oncologists, radiotherapists, and surgical oncologists in India. Only one oncologist handles every 2,000 cancer patients in the nation, which has 1.8 million cancer patients. Despite the existence of a sizable target patient population, it is anticipated that the shortage of oncologists and radiologists in a number of nations around the world will have an impact on the adoption of interventional oncology procedures in their individual healthcare systems.

Interventional Oncology Market Report Findings https://www.globalinsightservices.com/reports/interventional-oncology-market/

The embolization devices segment is anticipated to dominate the market during the forecast period

Based on the product, it is segmented into embolization devices, ablation devices, and support devices. The embolization devices segment is anticipated to dominate the market during the forecast period. Although these tools are largely used to treat hepatocellular carcinoma, their use to numerous other cancer types has been greatly expanded. When ablation procedures cannot be utilized to treat a tumor or when the tumor is big, these devices are used. In order to enhance the results of liver resection, they are frequently employed in palliative treatments and as a pre-operative therapy.

Both radioembolic and non-radioactive embolic agents are classified as embolic agents. Gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol are examples of non-radioactive emboli (PVA). Gelatin foam is a transitory embolic agent with a relatively short-lived effect. It is a non-radioactive embolic agent. Permanent embolic agents are those whose effects last for a longer time and are non-radioactive.

The thermal tumor ablation segment is anticipated to dominate the market during the forecast period

Based on the procedure, it is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization, transcatheter arterial radioembolization, and transcatheter arterial embolization. The thermal tumor ablation segment is anticipated to dominate the market during the forecast period. Together with medical, surgical, and radiation oncology, interventional oncology has emerged as a cornerstone of cancer treatment. The interventional oncology program uses image guidance to guide targeted, minimally invasive operations that are used to diagnose, treat, and/or relieve cancer symptoms.

The liver cancer segment accounted for the largest share of the interventional oncology market

Based on the type, it is segmented into liver cancer, lung cancer, bone metastasis, kidney cancer, breast cancer, prostate cancer, and other cancers. The liver cancer segment accounted for the largest share of the interventional oncology market. Since surgically removing the tumor may not leave the surrounding tissue healthy enough for the liver to function properly, interventional oncology is essential in the treatment of liver cancer. Therefore, interventional oncology treatments can be used to effectively treat primary liver tumors as well as liver tumors brought on by metastatic cancers. Because of this, interventional oncology is used in more than half of all therapies for both primary and metastatic liver cancer.

The significant market share of this segment may be attributable to a number of factors, including the rising incidence of liver cancer worldwide and the expansion of research and development efforts to create sophisticated interventional oncology-based liver cancer therapies. Initiatives in the form of grants and funding for the creation of cutting-edge therapies utilizing interventional oncology also contribute to market expansion.

The hospitals & diagnostics centers segment accounted for the largest share of the interventional oncology market

Based on the end user, it is segmented into hospitals, ambulatory surgery centers, and research & academic institutes. The hospitals & diagnostics centers segment accounted for the largest share of the interventional oncology market. There is a constant need for hospital-based care since there are modern facilities for treating illnesses and injuries and skilled staff available. Another important factor influencing market growth is the fact that hospitals see a lot more patients than other healthcare facilities. A wide variety of surgical operations are regularly carried out in hospitals, and the majority of these surgeries are done while the patient is an inpatient. The adoption of robotic surgery as well as the rise in the use of electrosurgery and minimally invasive surgeries in hospitals are principally responsible for this segment’s growth.

Asia Pacific region is anticipated to dominate the market during the forecast period

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific region is anticipated to dominate the market during the forecast period. The major factors influencing the growth of the APAC interventional oncology market are government initiatives to increase funding, supportive regulations for the development and commercialization of advanced interventional oncology products, rising healthcare expenditure, expanding hospitals and clinics in China and India, expanding research bases across China, Japan, and India, and rising surgical incidence.

Recent Developments

• March 2021, Boston Scientific launched the Thera Sphere Y-90 Glass Microspheres.
• December 2018, Merit Medical Systems launched the Preclude Ideal Hydrophilic Sheath Introducer in EMEA markets.
• December 2018, Medical City and distributor Gulf Medical Company to install the first IMRIS Surgical Theatre in Saudi Arabia.
• November 2018, IMBiotechnologies launched ‘Ekobi 500 Embolization Microspheres’ with an enahced feature of detectability using ultrasound technology.
• April 2018, Medtronic launched its Opti Sphere embolization spheres designed for hypervascular tumor embolization in the US.

Interventional Oncology Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global Interventional Oncology market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of market trends and restraints is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future Interventional Oncology market potential from 2021 to 2031 in terms of revenue.
• Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Interventional Oncology market are also analyzed.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global Interventional Oncology industry.

Global Interventional Oncology Market Segmentation

By Product

• Embolization Devices
• Ablation Devices
• Support Devices

By Procedure

• Thermal Tumor Ablation
• Non-Thermal Tumor Ablation
• Transcatheter Arterial Chemoembolization
• Transcatheter Arterial Radioembolization
• Transcatheter Arterial Embolization

By Cancer Type

• Liver Cancer
• Lung Cancer
• Bone Metastasis
• Kidney Cancer
• Breast Cancer
• Prostate Cancer
• Other Cancers

By End Users

• Hospitals
• Ambulatory Surgery Centers
• Research & Academic Institutes

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • The UK
  • Germany
  • France
  • Spain
  • Rest of Europe
• The Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World
  • Latin America
  • The Middle East
  • Africa

Key Players

Medtronic (Ireland)

Boston Scientific (US)

BD (US)

Terumo (Japan)

Merit Medical (US)

AngioDynamics (US)

J&J (US)

Teleflex (US)

Cook Medical (US)

HealthTronics (US)

MedWaves (US)

Sanarus (US)

IMBiotechnologies (Canada)

Trod Medical (US)